There is a broad consensus in the medical community in support of Duchenne newborn screening and we in Connecticut are hoping ...

Researchers, physicians, families and affected patients view Duchenne muscular dystrophy (DMD) as a neuromuscular condition. Children are diagnosed during the first years of life because they have ...

Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with ...

Givinostat should be available to people with Duchenne muscular dystrophy through a type of compassionate use scheme.

Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...

Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...

In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

If you’re living with Duchenne muscular dystrophy (DMD), planning ahead can help support the success of future education, employment, and housing efforts. Duchenne muscular dystrophy (DMD ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...